Guangdong Zhongsheng Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2001-12-31
- Employees
- 1.7K
- Market Cap
- -
- Website
- http://www.zspcl.com
Clinical Trials
5
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (100.0%)A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Phase 1
- Conditions
- Small Cell Lung CancerMedulloblastomaNeuroendocrine NeoplasmBasal Cell CarcinomaGlioblastomaAdenocarcinoma of Esophagogastric Junction
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT03734913
- Locations
- 🇨🇳
Jilin Cancer Hospital, Chang Chun, Jilin, China
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
Phase 1
- Conditions
- CholangiocarcinomaHepatocellular CarcinomaGastric CancerEsophageal CancerColorectal Cancer
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT03734926
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: ZSP1273 High DoseDrug: ZSP1273 900 mgDrug: ZSP1273 100 mgDrug: ZSP1273 200 mgDrug: ZSP1273 400 mgDrug: ZSP1273 600 mgDrug: ZSP1273 1200 mgDrug: ZSP1273 Low DoseDrug: ZSP1273 Median DoseDrug: Placebo 1200 mgDrug: Placebo 600 mgDrug: PlaceboDrug: Placebo 200 mgDrug: Placebo 400 mgDrug: Placebo 900 mgDrug: Placebo 100 mg
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Target Recruit Count
- 103
- Registration Number
- NCT03679143
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
Phase 1
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis(IPF)Solid Tumor
- Interventions
- Drug: ZSP1603 12.5 mgDrug: ZSP1603 7.5 mgDrug: ZSP1603 25 mgDrug: ZSP1603 50 mgDrug: Placebo 12.5mgDrug: Placebo 25mgDrug: Placebo 50mg
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03619616
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics
Phase 1
Completed
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Drug: ZSP1601 25 mgDrug: ZSP1601 50 mgDrug: ZSP1601 100 mgDrug: ZSP1601 175 mgDrug: ZSP1601 275 mgDrug: ZSP1601 350 mgDrug: Placebo 25mgDrug: Placebo 50 mgDrug: Placebo 175 mgDrug: Placebo 275 mgDrug: Placebo 350mgDrug: Placebo 100mgDrug: Placebo 100 mg
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT03392779
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
News
No news found